Safety and Feasibility of an Endotoxemia Model

Safety and Feasibility of an Endotoxemia Model: Pilot Study

The purpose of this study is to establish the safety and feasibility of low dose LPS administration to a small subset of humans in preparation for a larger USDA funded study examining what is the lowest effective dose of EPA + DHA (300, 600, 900 and 1,800 mg/day delivered as fish oil supplements) that significantly attenuates the inflammatory response the investigators wish to examine the effects of an endotoxemia model for inducing inflammation. Based on previous research, low dose LPS administration affects metabolism in humans with only minimal clinical effects (such as "flu" like illness). Therefore, each of the six subjects included in this small pilot study will receive a low dose of LPS and placebo in order to learn more about the metabolic changes that occur during administration and inflammation. The investigators hypothesis that LPS administration will elicit only minimal clinical effects (such as "flu" like illness) when compared to placebo (saline--water with the same amount of salt as in your blood).

Study Overview

• Status: Completed
• Conditions: Inflammation; Cardiovascular Disease
• Intervention / Treatment: Drug: LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • University Park, Pennsylvania, United States, 16802
      • Penn State University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 35 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy men and non-pregnant/lactating women between the ages of 20 and 35 years old
• BMI > 19.9 and < 30.0
• Able to give written informed consent and willing to comply with all study- related procedures

Exclusion Criteria:

• Previous history of heart disease or diabetes
• Renal Insufficiency
• Chronic anti-inflammatory use
• Systolic blood pressure < 90
• Individuals currently using tobacco products or have done so in the previous 30 days
• Individuals taking Omega-3 fatty acid supplements or their usual intake of fish is greater than 3-4 servings per month

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LPS; LPS will be injected at a dose of 0.6 ng/kg body weight through a catheter by a trained GCRC staff member involved with this study.	Drug: LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP); LPS or placebo (saline-salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.
Placebo Comparator: Saline; A saline solution will be injected through a catheter by a trained GCRC staff member involved with this study.	Drug: LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP); LPS or placebo (saline-salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change in Inflammatory Markers	Baseline (before LPS administration), 1, 2, 3, 4, 6, 12, 24 hrs post LPS administration; 2, 3 and 5 days post LPS administration

Secondary Outcome Measures

Outcome Measure	Time Frame
Change in Lipid Mediators	1, 2, 3 and 5 days post LPS administration

Collaborators and Investigators

• Sponsor: Penn State University
• Collaborators: United States Department of Agriculture (USDA)
• Investigators: Principal Investigator: Penny M Kris-Etherton, PhD, RD, Penn State University

Study record dates

Study Major Dates

• Study Start: April 1, 2011
• Primary Completion (Actual): August 1, 2011
• Study Completion (Actual): September 1, 2011

Study Registration Dates

• First Submitted: April 1, 2011
• First Submitted That Met QC Criteria: April 5, 2011
• First Posted (Estimated): April 6, 2011

Study Record Updates

• Last Update Posted (Actual): August 21, 2023
• Last Update Submitted That Met QC Criteria: August 16, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: Cardiovascular disease; Inflammation; Endotoxin; LPS
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Systemic Inflammatory Response Syndrome; Sepsis; Bacteremia; Toxemia; Cardiovascular Diseases; Inflammation; Endotoxemia
• Other Study ID Numbers: PKE LPSpilot